HMR Lignans for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

HMR Lignans for Health & Longevity

Created on 06/17/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A Norway spruce extract converted by gut bacteria into enterolactone, a very weak estrogen-like compound. The best human evidence is modest: the higher dose meaningfully reduced weekly hot flashes in postmenopausal women, and it was well tolerated. Broader heart and cancer claims rest on diet and animal data, not trials of this product. (Full Review)

Protocol

Standard Dose
36–72 mg/day 7-HMR
72 mg/day produced the meaningful hot-flash reduction; oral, for 8 weeks in postmenopausal women
Timing
Once daily with food
No clear time-of-day advantage; food may aid the gut-bacterial conversion step
Titration
Start at ~36 mg/day
Begin lower before moving to 72 mg/day to assess tolerance
Time to effect
Blood Enterolactone
Days to weeks
Rises within days to weeks of starting
Single-Dose Peak
~24 hours
Enterolactone peaks ~24 h after a dose; 7-HMR peaks ~1 h
Hot-Flash Relief
Over 8 weeks
Larger reduction by week 8; expect weeks, not days

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Premenopausal women with elevated breast cancer risk
  • Active hormone-sensitive cancers (estrogen receptor-positive breast, endometrial) without oncologist guidance
  • Premenopausal women with high familial breast-cancer risk (e.g., BRCA pathogenic variants)
    •
Key Interactions
  • Hormone replacement therapy (estradiol-containing products)
  • Selective estrogen receptor modulators (tamoxifen, raloxifene)
  • Other phytoestrogen supplements (soy isoflavones, red clover, flaxseed lignans)
  • Additive-effect supplements raising enterolactone (flaxseed, sesame lignans); antioxidant supplements (vitamin E)
  • Recent broad-spectrum antibiotics
    •

Risk & Side Effects

  • High: [risks_high]
    •
  • Medium: Theoretical hormone-sensitive tissue stimulation
    •
  • Low: Mild gastrointestinal and general adverse events; reproductive/endocrine effects at high doses
    •
  • Speculative: Drug-level interaction via estrogen pathways; altered mineral or vitamin status
    •

Monitoring

Marker Target Why
Serum/urine enterolactone Higher within population range (no formal optimal cutoff) Confirms gut conversion of 7-HMR to the active compound
Fasting lipid panel (LDL) LDL well within healthy range (functional target often <100 mg/dL) Tracks possible cardiovascular/antioxidant effect
Fasting glucose / HbA1c Glucose 70–85 mg/dL; HbA1c <5.4% (functional) Tracks possible metabolic benefit seen in animal models

Cadence: Reassess symptom response at ~4 and 8 weeks; review hormone-sensitive health status every 6–12 months for longer-term use

Qualitative Assessment

  • Night sweat frequency and sleep continuity
  • Overall sleep quality
  • Daytime energy and mood stability
  • General sense of menopausal comfort
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.